Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing antibody therapeutics to treat solid tumors and hematologic malignancies. The company is leveraging its proprietary StitchMabs and common light-chain enabled multi specific platforms to identify multi specifics and combinations of antibody therapeutics that could be advanced to the clinic. Its lead product candidate is CTX-471, a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells that is being evaluated in a Phase 1 study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors and who subsequently relapsed or progressed after a period of stable disease. The company is also developing CTX-8371, a bispecific antibody that targets PD-1 and PD-L1. In addition, it is developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: compasstherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/2/2025 | $6.00 | Market Perform → Outperform | Leerink Partners |
| 2/24/2025 | $12.00 | Buy | Guggenheim |
| 2/19/2025 | $12.00 | Overweight | Piper Sandler |
| 12/23/2024 | $32.00 | Buy | D. Boral Capital |
| 11/15/2024 | $5.00 → $4.00 | Outperform → Market Perform | Leerink Partners |
| 9/16/2024 | $5.00 | Neutral → Buy | Ladenburg Thalmann |
| 1/31/2023 | $8.00 | Buy | Jefferies |
| 1/27/2023 | $9.00 | Buy | Stifel |
| 5/23/2022 | $12.00 | Buy | H.C. Wainwright |
| 3/15/2022 | $7.00 | Buy | Ladenburg Thalmann |